Field Medical has announced the successful close of its $35 million oversubscribed Series B funding round, marking a significant milestone in the advancement of its proprietary FieldForce™ Pulsed Field Ablation (PFA) platform. The investment, led by new and existing healthcare-focused investors, is set to accelerate the company’s development efforts, particularly its flagship VERITAS clinical trial. Field Medical’s platform is designed to address the growing need for safer and more effective ablation therapies, with a focus on treating high-risk ventricular tachycardia (VT) and atrial fibrillation (AF)—conditions that remain leading contributors to cardiovascular morbidity and mortality.
At the core of Field Medical’s innovation is its ultra-low energy, high-precision PFA system, engineered to selectively ablate cardiac tissue while preserving surrounding structures like the esophagus and phrenic nerve. This tissue-selectivity could significantly reduce the risk of complications often seen with traditional thermal-based ablation techniques. With the new capital infusion, Field Medical will expand its R&D efforts, scale clinical operations, and further refine the FieldForce™ platform to optimize procedural control, energy delivery, and physician usability. The funding also supports the company’s regulatory strategy, aiming to bring the system closer to commercialization.
In parallel with the funding announcement, Field Medical has also strengthened its scientific advisory board and executive team by adding prominent electrophysiologists and medtech leaders, signaling its readiness for clinical and commercial scale-up. The company’s mission—to redefine safety and efficacy standards in electrophysiology—is supported by a growing body of clinical interest in PFA as a next-generation modality. With its differentiated technology and a strong foundation of financial and clinical support, Field Medical is well-positioned to impact the future of arrhythmia care, offering patients and physicians a safer, faster, and more targeted ablation solution.
MedTech Spectrum's Summary
Significant Funding Milestone: Field Medical’s $35 million oversubscribed Series B round will accelerate development of its FieldForce™ Pulsed Field Ablation (PFA) platform and support key clinical trials, including the VERITAS study for high-risk ventricular tachycardia.
Next-Generation Ablation Technology: The FieldForce™ system offers ultra-low energy, tissue-selective PFA designed to enhance procedural safety and precision—minimizing damage to surrounding tissue compared to traditional ablation methods.
Strengthened Leadership and Momentum: With expanded advisory and executive teams and growing investor confidence, Field Medical is poised to transform cardiac ablation care by advancing safer, more effective treatment options for arrhythmia patients.
